Daphne Day – Projects — Monash University

View Scopus Profile

Research activity per year

If you made any changes in Pure these will be visible here soon.

1 Finished
24 Active

25 results

Active

Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors
Day, D.
21/07/23 → 20/07/28
Project: Research
A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti–PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
Day, D.
22/05/23 → 21/05/28
Project: Research
A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Day, D.
3/05/23 → 2/05/28
Project: Research
A Phase I, Open-label, Multicenter, First in Human Study to Evaluate the Safety and Tolerability of HH3806 in Patients with Advanced Malignancies
Day, D.
19/04/23 → 18/04/28
Project: Research
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Day, D.
6/12/22 → 5/12/27
Project: Research
A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects with Advanced/Metastatic Solid Tumors
Day, D.
5/12/22 → 4/12/27
Project: Research
Open-Label, DA Phase 1a/1b, Multicenter, ose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK127 in Combination with AK104 in Subjects with Advanced or Metastatic Solid Tumors
Day, D.
2/12/21 → 1/12/26
Project: Research
A Phase 1 Dose Escalation and Dose Expansion Open-label, Multicenter, Study of OP-1250 in Combination with the CDK4/6 Inhibitor Palbociclib in Adult Subjects with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer
Day, D.
16/11/21 → 15/11/26
Project: Research
A Phase I/II Trial of EMB-02, a Bi-specific Antibody against PD-1 and LAG3, in Patients with Advanced Solid Tumors
Day, D.
27/10/21 → 26/10/26
Project: Research
A Phase II, Open Label, Multicenter Study Of Olinvacimab In Combination with Pembrolizumab In Patients With Metastatic Triple-Negative Breast Cancer
Day, D.
30/09/21 → 29/09/26
Project: Research
A Phase 1 bioequivalence study between the current commercial formulation and the proposed soft gel capsule formulation of talazoparib, and food effect study for the proposed talazoparib soft gel capsule formulation in participants with advanced solid tumor
Day, D.
13/01/21 → 12/01/26
Project: Research
A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and levnatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)
Day, D.
28/08/20 → 27/08/25
Project: Research
Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Day, D.
13/08/20 → 12/08/25
Project: Research
A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-Tumor Activity of ABBV321 in Subjects with Advanced Solid Tumors Associated with Overexpression of the Epidermal Growth Factor Receptor (EGFR)
Day, D.
21/07/20 → 20/07/25
Project: Research
A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to evaluate Intratumoral MK-1454 in Combination with IV Pembrolizumab vs IV Pembrolizumab Monotherapy
Day, D.
24/02/20 → 23/02/25
Project: Research
A Phase I study of MAX-10181 given orally to patients with advanced solid tumors
Day, D. & Frentzas, S.
10/02/20 → 9/02/25
Project: Research
A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of HBM4003 Monotherapy in Subjects with Advanced Solid Tumors
Parakh, S. & Day, D.
24/09/19 → 23/09/24
Project: Research
A Phase la/lb, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors
Day, D. & Markman, B.
6/06/19 → 5/06/24
Project: Research
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab Versus Extreme Study Revgimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) As First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Alamgeer, M. & Day, D.
12/02/19 → 11/02/24
Project: Research
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab (BMS-936558, anti-PD-1 Monoclonal Antibody) in Advanced Cancers
Markman, B., Day, D. & Body, A.
29/01/19 → 28/01/24
Project: Research
A Phase I/IIa Study of BMS 986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects with Select Advanced Solid Tumors
Day, D., Markman, B. & Body, A.
12/12/18 → 11/12/23
Project: Research
A Phase 1/2 Multicentre Study of BMS-986012 in Subjects with Relapsed/Refractory Small Cell Lung Cancer
Day, D. & Markman, B.
12/12/18 → 11/12/23
Project: Research
A Phase 1, Multicenter, Open-label, Multiple Dose escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects with Advanced Cancers with HER2 Expression
Day, D.
16/11/18 → 15/11/24
Project: Research
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors
Markman, B. & Day, D.
16/11/18 → 15/11/23
Project: Research
Finished

‘Prospective characterisation of a novel circulating tumour-derived DNA methylation assay to monitor tumour burden and response to therapy in metastatic colorectal cancer (CATCHER-1)’
Segelov, E. & Day, D.
9/09/19 → 8/09/20
Project: Research